Journal of Life Science (생명과학회지)

Korean Society of Life Science (한국생명과학회)
권호 표지
DOI QR코드

DOI QR Code

Cathepsin S as a Cancer Therapeutic Target

암 치료 표적으로써 cathepsin S

  • Woo, Seon Min (Department of Immunology, School of Medicine, Keimyung University) ;
  • Kwon, Taeg Kyu (Department of Immunology, School of Medicine, Keimyung University)
  • 우선민 (계명대학교 의과대학 면역학교실) ;
  • 권택규 (계명대학교 의과대학 면역학교실)
  • Received : 2018.05.16
  • Accepted : 2018.06.09
  • Published : 2018.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Cysteine cathepsins are lysosomal enzymes that belong to the papain family and can induce the degradation of damaged proteins through the endo-lysosomal pathway. It is highly upregulated in many cancers by regulating gene amplification and transcriptional, translational, and post-transcriptional modifications. Cathepsin S is part of the cysteine cathepsin family. Many studies have demonstrated that cathepsin S not only plays a specific role in MHC class II antigen presentation but also plays a crucial role in cancers. Cathepsin S is more stable at a neutral pH compared to other cysteine cathepsins, which supports the importance of cathepsin S in disease microenvironments. Therefore, the dysregulation of cathepsin S has participated in a variety of pathological processes, including cancer, arthritis, and cardiovascular disease. Furthermore, a decrease or depletion in the expression of cathepsin S has been implicated in the processes of tumor growth, invasion, metastasis, and angiogenesis. Taken together, cathepsin S has been suggested as an attractive therapeutic target for cancer therapy. In this review, the known involvement of cathepsin S in diseases, particularly with respect to recent work indicating its role in cancer therapy, is examined. An overview of current literature on the inhibitors of cathepsin S as a therapeutic target for cancer is also provided.

Cathepsin은 리소좀에 존재하는 효소로, 엔도좀-리소좀 경로를 통하여 손상된 단백질의 분해를 유도한다. 이러한 cathepsin은 활성화되는 촉매 잔기 위치(catalytic residue site)에 따라 cysteine, aspartate, serine cathepsin으로 나뉜다. 다양한 암세포에서 cysteine cathepsin은 유전자 증폭이나 전사, 번역, 전사 후 단계를 통해 높은 발현을 유지한다. 특히 cathepsin S의 경우, 다른 cysteine cathepsin과 달리 중성 pH 환경에서도 안정적으로 활성도를 유지하며 특정 조직에서 발현이 제한적이라는 특징을 가지고 있기 때문에 질병의 미세환경에서 중요한 역할을 한다. 면역세포에서의 cathepsin S는 불변 사슬(invariant chain)을 분해하여 항원 제시에 중요한 MHC class II의 활성화를 통해 면역 반응을 조절하며, 암세포에서의 cathepsin S는 전이와 혈관신생을 조절함으로써 암세포의 성장을 증가시키는 역할을 한다. Cathepsin S의 발현 조절에 문제가 생기면 암, 관절염, 심혈관 질환을 포함한 많은 병리학적 현상에 영향을 미친다. 특히 암세포에서 cathepsin S의 발현 억제와 결함은 혈관신생을 억제시킬 뿐만아니라, 암세포의 성장과 전이를 감소시키고 세포사멸을 유도한다. 따라서, cathepsin S는 암 치료에 있어 좋은 표적이 될 수 있다.

Keywords

References

  1. Alatrash, G., Garber, H. R., Zhang, M., Sukhumalchandra, P., Qiu, Y., Jakher, H., Perakis, A. A., Becker, L., Yoo, S. Y., Dwyer, K. C., Coombes, K., Talukder, A. H., John, L. S. S., Senyukov, V., Lee, D. A., Sergeeva, A., He, H., Ma, Q., Armistead, P. M., Roszik, J., Mittendorf, E. A., Molldrem, J. J., Hawke, D., Lizee, G. and Kornblau, S. M. 2017. Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target. Leukemia 31, 234-237. https://doi.org/10.1038/leu.2016.249
  2. Appelqvist, H., Waster, P., Kagedal, K. and Ollinger, K. 2013. The lysosome: from waste bag to potential therapeutic target. J. Mol. Cell. Biol. 5, 214-226. https://doi.org/10.1093/jmcb/mjt022
  3. Azuma, T., Yamada, M., Murakita, H., Nishikawa, Y., Kohli, Y., Yamamoto, K. and Hori, H. 1995. Cathepsin E expressed in pancreatic cancer. Adv. Exp. Med. Biol. 362, 363-366.
  4. Barrett, A. J., Kembhavi, A. A., Brown, M. A., Kirschke, H., Knight, C. G., Tamai, M. and Hanada, K. 1982. L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. Biochem. J. 201, 189-198. https://doi.org/10.1042/bj2010189
  5. Baugh, M., Black, D., Westwood, P., Kinghorn, E., McGregor, K., Bruin, J., Hamilton, W., Dempster, M., Claxton, C., Cai, J., Bennett, J., Long, C., McKinnon, H., Vink, P., den Hoed, L., Gorecka, M., Vora, K., Grant, E., Percival, M. D., Boots, A. M. and van Lierop, M. J. 2011. Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity. J. Autoimmun. 36, 201-209. https://doi.org/10.1016/j.jaut.2011.01.003
  6. Bell-McGuinn, K. M., Garfall, A. L., Bogyo, M., Hanahan, D. and Joyce, J. A. 2007. Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer. Cancer Res. 67, 7378-7385. https://doi.org/10.1158/0008-5472.CAN-07-0602
  7. Berger, A. B., Vitorino, P. M. and Bogyo, M. 2004. Activitybased protein profiling: applications to biomarker discovery, in vivo imaging and drug discovery. Am. J. Pharmacogenomics 4, 371-381. https://doi.org/10.2165/00129785-200404060-00004
  8. Burden, R. E., Gormley, J. A., Jaquin, T. J., Small, D. M., Quinn, D. J., Hegarty, S. M., Ward, C., Walker, B., Johnston, J. A., Olwill, S. A. and Scott, C. J. 2009. Antibody-mediated inhibition of cathepsin S blocks colorectal tumor invasion and angiogenesis. Clin. Cancer Res. 15, 6042-6051. https://doi.org/10.1158/1078-0432.CCR-09-1262
  9. Burden, R. E., Gormley, J. A., Kuehn, D., Ward, C., Kwok, H. F., Gazdoiu, M., McClurg, A., Jaquin, T. J., Johnston, J. A., Scott, C. J. and Olwill, S. A. 2012. Inhibition of Cathepsin S by Fsn0503 enhances the efficacy of chemotherapy in colorectal carcinomas. Biochimie 94, 487-493. https://doi.org/10.1016/j.biochi.2011.08.017
  10. Chai, Y., Wu, W., Zhou, C. and Zhou, J. 2012. The potential prognostic value of cathepsin D protein in serous ovarian cancer. Arch. Gynecol. Obstet. 286, 465-471. https://doi.org/10.1007/s00404-012-2318-2
  11. Chauhan, S. S., Goldstein, L. J. and Gottesman, M. M. 1991. Expression of cathepsin L in human tumors. Cancer Res. 51, 1478-1481.
  12. Chen, J. C., Uang, B. J., Lyu, P. C., Chang, J. Y., Liu, K. J., Kuo, C. C., Hsieh, H. P., Wang, H. C., Cheng, C. S., Chang, Y. H., Chang, M. D., Chang, W. S. and Lin, C. C. 2010. Design and synthesis of alpha-ketoamides as cathepsin S inhibitors with potential applications against tumor invasion and angiogenesis. J. Med. Chem. 53, 4545-4549. https://doi.org/10.1021/jm100089e
  13. Chen, K. L., Chang, W. S., Cheung, C. H., Lin, C. C., Huang, C. C., Yang, Y. N., Kuo, C. P., Kuo, C. C., Chang, Y. H., Liu, K. J., Wu, C. M. and Chang, J. Y. 2012. Targeting cathepsin S induces tumor cell autophagy via the EGFR-ERK signaling pathway. Cancer Lett. 317, 89-98. https://doi.org/10.1016/j.canlet.2011.11.015
  14. Codogno, P. and Meijer, A. J. 2005. Autophagy and signaling: their role in cell survival and cell death. Cell Death Differ. 12 Suppl 2, 1509-1518. https://doi.org/10.1038/sj.cdd.4401751
  15. Conus, S. and Simon, H. U. 2010. Cathepsins and their involvement in immune responses. Swiss Med. Wkly. 140, w13042.
  16. Costantino, C. M., Ploegh, H. L. and Hafler, D. A. 2009. Cathepsin S regulates class II MHC processing in human CD4+ HLA-DR+ T cells. J. Immunol. 183, 945-952. https://doi.org/10.4049/jimmunol.0900921
  17. Decock, J., Obermajer, N., Vozelj, S., Hendrickx, W., Paridaens, R. and Kos, J. 2008. Cathepsin B, cathepsin H, cathepsin X and cystatin C in sera of patients with early-stage and inflammatory breast cancer. Int. J. Biol. Markers 23, 161-168. https://doi.org/10.1177/172460080802300305
  18. Dian, D., Vrekoussis, T., Shabani, N., Mylonas, I., Kuhn, C., Schindlbeck, C., Navrozoglou, I., Friese, K., Makrigiannakis, A. and Jeschke, U. 2012. Expression of cathepsin-D in primary breast cancer and corresponding local recurrence or metastasis: an immunohistochemical study. Anticancer Res. 32, 901-905.
  19. Drenth, J., Jansonius, J. N., Koekoek, R., Swen, H. M. and Wolthers, B. G. 1968. Structure of papain. Nature 218, 929-932. https://doi.org/10.1038/218929a0
  20. Drevs, J., Muller-Driver, R., Wittig, C., Fuxius, S., Esser, N., Hugenschmidt, H., Konerding, M. A., Allegrini, P. R., Wood, J., Hennig, J., Unger, C. and Marme, D. 2002. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res. 62, 4015-4022.
  21. Driessen, C., Bryant, R. A., Lennon-Dumenil, A. M., Villadangos, J. A., Bryant, P. W., Shi, G. P., Chapman, H. A. and Ploegh, H. L. 1999. Cathepsin S controls the trafficking and maturation of MHC class II molecules in dendritic cells. J. Cell Biol. 147, 775-790. https://doi.org/10.1083/jcb.147.4.775
  22. Ebert, M. P., Kruger, S., Fogeron, M. L., Lamer, S., Chen, J., Pross, M., Schulz, H. U., Lage, H., Heim, S., Roessner, A., Malfertheiner, P. and Rocken, C. 2005. Overexpression of cathepsin B in gastric cancer identified by proteome analysis. Proteomics 5, 1693-1704. https://doi.org/10.1002/pmic.200401030
  23. Fan, Q., Wang, X., Zhang, H., Li, C., Fan, J. and Xu, J. 2012. Silencing cathepsin S gene expression inhibits growth, invasion and angiogenesis of human hepatocellular carcinoma in vitro. Biochem. Biophys. Res. Commun. 425, 703-710. https://doi.org/10.1016/j.bbrc.2012.07.013
  24. Fan, X., Wang, C., Song, X., Liu, H., Li, X. and Zhang, Y. 2018. Elevated Cathepsin K potentiates metastasis of epithelial ovarian cancer. Histol. Histopathol. 11960.
  25. Fernandez, P. L., Farre, X., Nadal, A., Fernandez, E., Peiro, N., Sloane, B. F., Shi, G. P., Chapman, H. A., Campo, E. and Cardesa, A. 2001. Expression of cathepsins B and S in the progression of prostate carcinoma. Int. J. Cancer 95, 51-55. https://doi.org/10.1002/1097-0215(20010120)95:1<51::AID-IJC1009>3.0.CO;2-J
  26. Firestein, G. S. 2005. Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J. Clin. Rheumatol. 11, S39-44. https://doi.org/10.1097/01.rhu.0000166673.34461.33
  27. Flannery, T., Gibson, D., Mirakhur, M., McQuaid, S., Greenan, C., Trimble, A., Walker, B., McCormick, D. and Johnston, P. G. 2003. The clinical significance of cathepsin S expression in human astrocytomas. Am. J. Pathol. 163, 175-182. https://doi.org/10.1016/S0002-9440(10)63641-3
  28. Flannery, T., McQuaid, S., McGoohan, C., McConnell, R. S., McGregor, G., Mirakhur, M., Hamilton, P., Diamond, J., Cran, G., Walker, B., Scott, C., Martin, L., Ellison, D., Patel, C., Nicholson, C., Mendelow, D., McCormick, D. and Johnston, P. G. 2006. Cathepsin S expression: An independent prognostic factor in glioblastoma tumours--A pilot study. Int. J. Cancer 119, 854-860. https://doi.org/10.1002/ijc.21911
  29. Georges, S., Ruiz Velasco, C., Trichet, V., Fortun, Y., Heymann, D. and Padrines, M. 2009. Proteases and bone remodelling. Cytokine Growth Factor Rev. 20, 29-41. https://doi.org/10.1016/j.cytogfr.2008.11.005
  30. Gocheva, V. and Joyce, J. A. 2007. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 6, 60-64. https://doi.org/10.4161/cc.6.1.3669
  31. Gocheva, V., Zeng, W., Ke, D., Klimstra, D., Reinheckel, T., Peters, C., Hanahan, D. and Joyce, J. A. 2006. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 20, 543-556. https://doi.org/10.1101/gad.1407406
  32. Gong, F., Peng, X., Luo, C., Shen, G., Zhao, C., Zou, L., Li, L., Sang, Y., Zhao, Y. and Zhao, X. 2013. Cathepsin B as a potential prognostic and therapeutic marker for human lung squamous cell carcinoma. Mol. Cancer 12, 125. https://doi.org/10.1186/1476-4598-12-125
  33. Gormley, J. A., Hegarty, S. M., O'Grady, A., Stevenson, M. R., Burden, R. E., Barrett, H. L., Scott, C. J., Johnston, J. A., Wilson, R. H., Kay, E. W., Johnston, P. G. and Olwill, S. A. 2011. The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study. Br. J. Cancer 105, 1487-1494. https://doi.org/10.1038/bjc.2011.408
  34. Huang, C. C., Chen, K. L., Cheung, C. H. and Chang, J. Y. 2013. Autophagy induced by cathepsin S inhibition induces early ROS production, oxidative DNA damage, and cell death via xanthine oxidase. Free Radic. Biol. Med. 65, 1473-1486. https://doi.org/10.1016/j.freeradbiomed.2013.07.020
  35. Ishida, M., Kojima, F. and Okabe, H. 2013. Cathepsin K expression in basal cell carcinoma. J. Eur. Acad. Dermatol. Venereol. 27, e128-130. https://doi.org/10.1111/j.1468-3083.2011.04436.x
  36. Jechorek, D., Votapek, J., Meyer, F., Kandulski, A., Roessner, A. and Franke, S. 2014. Characterization of cathepsin X in colorectal cancer development and progression. Pathol. Res. Pract. 210, 822-829. https://doi.org/10.1016/j.prp.2014.08.014
  37. Jedinak, A. and Maliar, T. 2005. Inhibitors of proteases as anticancer drugs. Neoplasma 52, 185-192.
  38. Johansson, A. C., Appelqvist, H., Nilsson, C., Kagedal, K., Roberg, K. and Ollinger, K. 2010. Regulation of apoptosis-associated lysosomal membrane permeabilization. Apoptosis 15, 527-540. https://doi.org/10.1007/s10495-009-0452-5
  39. Joyce, J. A., Baruch, A., Chehade, K., Meyer-Morse, N., Giraudo, E., Tsai, F. Y., Greenbaum, D. C., Hager, J. H., Bogyo, M. and Hanahan, D. 2004. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 5, 443-453. https://doi.org/10.1016/S1535-6108(04)00111-4
  40. Joyce, J. A. and Hanahan, D. 2004. Multiple roles for cysteine cathepsins in cancer. Cell Cycle 3, 1516-1619. https://doi.org/10.4161/cc.3.12.1289
  41. Kawakubo, T., Yasukochi, A., Toyama, T., Takahashi, S., Okamoto, K., Tsukuba, T., Nakamura, S., Ozaki, Y., Nishigaki, K., Yamashita, H. and Yamamoto, K. 2014. Repression of cathepsin E expression increases the risk of mammary carcinogenesis and links to poor prognosis in breast cancer. Carcinogenesis 35, 714-726. https://doi.org/10.1093/carcin/bgt373
  42. Kirschke, H., Wiederanders, B., Bromme, D. and Rinne, A. 1989. Cathepsin S from bovine spleen. Purification, distribution, intracellular localization and action on proteins. Biochem. J. 264, 467-473. https://doi.org/10.1042/bj2640467
  43. Kondo, Y., Kanzawa, T., Sawaya, R. and Kondo, S. 2005. The role of autophagy in cancer development and response to therapy. Nat. Rev. Cancer 5, 726-734. https://doi.org/10.1038/nrc1692
  44. Konduri, S., Lakka, S. S., Tasiou, A., Yanamandra, N., Gondi, C. S., Dinh, D. H., Olivero, W. C., Gujrati, M. and Rao, J. S. 2001. Elevated levels of cathepsin B in human glioblastoma cell lines. Int. J. Oncol. 19, 519-524.
  45. Konno-Shimizu, M., Yamamichi, N., Inada, K., Kageyama- Yahara, N., Shiogama, K., Takahashi, Y., Asada-Hirayama, I., Yamamichi-Nishina, M., Nakayama, C., Ono, S., Kodashima, S., Fujishiro, M., Tsutsumi, Y., Ichinose, M. and Koike, K. 2013. Cathepsin E is a marker of gastric differentiation and signet-ring cell carcinoma of stomach: a novel suggestion on gastric tumorigenesis. PLoS One 8, e56766. https://doi.org/10.1371/journal.pone.0056766
  46. Kos, J., Sekirnik, A., Kopitar, G., Cimerman, N., Kayser, K., Stremmer, A., Fiehn, W. and Werle, B. 2001. Cathepsin S in tumours, regional lymph nodes and sera of patients with lung cancer: relation to prognosis. Br. J. Cancer 85, 1193-1200. https://doi.org/10.1054/bjoc.2001.2057
  47. Kozlowski, L., Wojtukiewicz, M. Z. and Ostrowska, H. 2000. Cathepsin A activity in primary and metastatic human melanocytic tumors. Arch. Dermatol. Res. 292, 68-71. https://doi.org/10.1007/s004030050012
  48. Kroemer, G. and Jaattela, M. 2005. Lysosomes and autophagy in cell death control. Nat. Rev. Cancer 5, 886-897. https://doi.org/10.1038/nrc1738
  49. Krueger, S., Kalinski, T., Hundertmark, T., Wex, T., Kuster, D., Peitz, U., Ebert, M., Nagler, D. K., Kellner, U., Malfertheiner, P., Naumann, M., Rocken, C. and Roessner, A. 2005. Up-regulation of cathepsin X in Helicobacter pylori gastritis and gastric cancer. J. Pathol. 207, 32-42. https://doi.org/10.1002/path.1820
  50. Kruszewski, W. J., Rzepko, R., Wojtacki, J., Skokowski, J., Kopacz, A., Jaskiewicz, K. and Drucis, K. 2004. Overexpression of cathepsin B correlates with angiogenesis in colon adenocarcinoma. Neoplasma 51, 38-43.
  51. Lecaille, F., Kaleta, J. and Bromme, D. 2002. Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design. Chem. Rev. 102, 4459-4488. https://doi.org/10.1021/cr0101656
  52. Lee-Dutra, A., Wiener, D. K. and Sun, S. 2011. Cathepsin S inhibitors: 2004-2010. Expert Opin. Ther. Pat. 21, 311-337. https://doi.org/10.1517/13543776.2011.553800
  53. Leto, G., Incorvaia, L., Flandina, C., Ancona, C., Fulfaro, F., Crescimanno, M., Sepporta, M. V. and Badalamenti, G. 2016. Clinical impact of cystatin C/cathepsin L and follistatin/activin A systems in breast cancer progression: A preliminary report. Cancer Invest. 34, 415-423. https://doi.org/10.1080/07357907.2016.1222416
  54. Leusink, F. K., Koudounarakis, E., Frank, M. H., Koole, R., van Diest, P. J. and Willems, S. M. 2018. Cathepsin K associates with lymph node metastasis and poor prognosis in oral squamous cell carcinoma. BMC Cancer 18, 385. https://doi.org/10.1186/s12885-018-4315-8
  55. Levicar, N., Strojnik, T., Kos, J., Dewey, R. A., Pilkington, G. J. and Lah, T. T. 2002. Lysosomal enzymes, cathepsins in brain tumour invasion. J. Neurooncol. 58, 21-32. https://doi.org/10.1023/A:1015892911420
  56. Libby, P., Ridker, P. M. and Maseri, A. 2002. Inflammation and atherosclerosis. Circulation 105, 1135-1143. https://doi.org/10.1161/hc0902.104353
  57. Littlewood-Evans, A. J., Bilbe, G., Bowler, W. B., Farley, D., Wlodarski, B., Kokubo, T., Inaoka, T., Sloane, J., Evans, D. B. and Gallagher, J. A. 1997. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res. 57, 5386-5390.
  58. Lohoefer, F., Reeps, C., Lipp, C., Rudelius, M., Zimmermann, A., Ockert, S., Eckstein, H. H. and Pelisek, J. 2012. Histopathological analysis of cellular localization of cathepsins in abdominal aortic aneurysm wall. Int. J. Exp. Pathol. 93, 252-258. https://doi.org/10.1111/j.1365-2613.2012.00819.x
  59. Lopez-Otin, C. and Bond, J. S. 2008. Proteases: multifunctional enzymes in life and disease. J. Biol. Chem. 283, 30433-30437. https://doi.org/10.1074/jbc.R800035200
  60. MacIntyre, A. C. and Cutler, D. J. 1988. The potential role of lysosomes in tissue distribution of weak bases. Biopharm. Drug Dispos. 9, 513-526. https://doi.org/10.1002/bod.2510090602
  61. Metaye, T., Kraimps, J. L., Goujon, J. M., Fernandez, B., Quellard, N., Ingrand, P., Barbier, J. and Begon, F. 1997. Expression, localization, and thyrotropin regulation of cathepsin D in human thyroid tissues. J. Clin. Endocrinol. Metab. 82, 3383-3388. https://doi.org/10.1210/jcem.82.10.4298
  62. Nagler, D. K., Kruger, S., Kellner, A., Ziomek, E., Menard, R., Buhtz, P., Krams, M., Roessner, A. and Kellner, U. 2004. Up-regulation of cathepsin X in prostate cancer and prostatic intraepithelial neoplasia. Prostate 60, 109-119. https://doi.org/10.1002/pros.20046
  63. Nguyen, D. X. and Massague, J. 2007. Genetic determinants of cancer metastasis. Nat Rev. Genet 8, 341-352.
  64. Nishikawa, H., Ozaki, Y., Nakanishi, T., Blomgren, K., Tada, T., Arakawa, A. and Suzumori, K. 2004. The role of cathepsin B and cystatin C in the mechanisms of invasion by ovarian cancer. Gynecol. Oncol. 92, 881-886. https://doi.org/10.1016/j.ygyno.2003.11.017
  65. Okudela, K., Mitsui, H., Woo, T., Arai, H., Suzuki, T., Matsumura, M., Kojima, Y., Umeda, S., Tateishi, Y., Masuda, M. and Ohashi, K. 2016. Alterations in cathepsin L expression in lung cancers. Pathol. Int. 66, 386-392. https://doi.org/10.1111/pin.12424
  66. Pandya, N. M., Dhalla, N. S. and Santani, D. D. 2006. Angiogenesis--a new target for future therapy. Vascul. Pharmacol. 44, 265-274. https://doi.org/10.1016/j.vph.2006.01.005
  67. Papetti, M. and Herman, I. M. 2002. Mechanisms of normal and tumor-derived angiogenesis. Am. J. Physiol. Cell Physiol. 282, C947-970. https://doi.org/10.1152/ajpcell.00389.2001
  68. Payne, C. D., Deeg, M. A., Chan, M., Tan, L. H., LaBell, E. S., Shen, T. and DeBrota, D. J. 2014. Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjects. Br. J. Clin. Pharmacol. 78, 1334-1342. https://doi.org/10.1111/bcp.12470
  69. Petricevic, S. J., Pavlovic, A., Capkun, V., Becic, K. and Durdov, M. G. 2017. Cathepsin K expression in melanoma is associated with metastases. Histol. Histopathol. 32, 711-716.
  70. Piao, S. and Amaravadi, R. K. 2016. Targeting the lysosome in cancer. Ann. N. Y. Acad. Sci. 1371, 45-54. https://doi.org/10.1111/nyas.12953
  71. Pozgan, U., Caglic, D., Rozman, B., Nagase, H., Turk, V. and Turk, B. 2010. Expression and activity profiling of selected cysteine cathepsins and matrix metalloproteinases in synovial fluids from patients with rheumatoid arthritis and osteoarthritis. Biol. Chem. 391, 571-579.
  72. Puente, X. S., Sanchez, L. M., Gutierrez-Fernandez, A., Velasco, G. and Lopez-Otin, C. 2005. A genomic view of the complexity of mammalian proteolytic systems. Biochem. Soc. Trans. 33, 331-334. https://doi.org/10.1042/BST0330331
  73. Qian, F., Frankfater, A., Steiner, D. F., Bajkowski, A. S. and Chan, S. J. 1991. Characterization of multiple cathepsin B mRNAs in murine B16a melanoma. Anticancer Res. 11, 1445-1451.
  74. Qin, Y., Cao, X., Guo, J., Zhang, Y., Pan, L., Zhang, H., Li, H., Tang, C., Du, J. and Shi, G. P. 2012. Deficiency of cathepsin S attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice. Cardiovasc. Res. 96, 401-410. https://doi.org/10.1093/cvr/cvs263
  75. Rofstad, E. K., Mathiesen, B., Kindem, K. and Galappathi, K. 2006. Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res. 66, 6699-6707. https://doi.org/10.1158/0008-5472.CAN-06-0983
  76. Ruan, H., Hao, S., Young, P. and Zhang, H. 2015. Targeting cathepsin B for cancer therapies. Horiz. Cancer Res. 56, 23-40.
  77. Ruan, J., Zheng, H., Rong, X., Rong, X., Zhang, J., Fang, W., Zhao, P. and Luo, R. 2016. Over-expression of cathepsin B in hepatocellular carcinomas predicts poor prognosis of HCC patients. Mol. Cancer 15, 17. https://doi.org/10.1186/s12943-016-0503-9
  78. Ruckrich, T., Brandenburg, J., Cansier, A., Muller, M., Stevanovic, S., Schilling, K., Wiederanders, B., Beck, A., Melms, A., Reich, M., Driessen, C. and Kalbacher, H. 2006. Specificity of human cathepsin S determined by processing of peptide substrates and MHC class II-associated invariant chain. Biol. Chem. 387, 1503-1511.
  79. Ruffell, B., Affara, N. I., Cottone, L., Junankar, S., Johansson, M., DeNardo, D. G., Korets, L., Reinheckel, T., Sloane, B. F., Bogyo, M. and Coussens, L. M. 2013. Cathepsin C is a tissue-specific regulator of squamous carcinogenesis. Genes Dev. 27, 2086-2098. https://doi.org/10.1101/gad.224899.113
  80. Santamaria, I., Velasco, G., Cazorla, M., Fueyo, A., Campo, E. and Lopez-Otin, C. 1998. Cathepsin L2, a novel human cysteine proteinase produced by breast and colorectal carcinomas. Cancer Res. 58, 1624-1630.
  81. Saraste, A. and Pulkki, K. 2000. Morphologic and biochemical hallmarks of apoptosis. Cardiovasc. Res. 45, 528-537. https://doi.org/10.1016/S0008-6363(99)00384-3
  82. Satelur, K. P. and Kumar, G. S. 2017. Immunohistochemical expression of cathepsin D in primary and recurrent squamous cell carcinoma. J. Contemp. Dent. Pract. 18, 795-801. https://doi.org/10.5005/jp-journals-10024-2129
  83. Schweiger, A., Christensen, I. J., Nielsen, H. J., Sorensen, S., Brunner, N. and Kos, J. 2004. Serum cathepsin H as a potential prognostic marker in patients with colorectal cancer. Int. J. Biol. Markers 19, 289-294. https://doi.org/10.1177/172460080401900406
  84. Seo, B. R., Min, K. J., Woo, S. M., Choe, M., Choi, K. S., Lee, Y. K., Yoon, G. and Kwon, T. K. 2017. Inhibition of cathepsin S induces mitochondrial ROS that sensitizes TRAIL-mediated apoptosis through p53-mediated downregulation of Bcl-2 and c-FLIP. Antioxid. Redox Signal. 27, 215-233. https://doi.org/10.1089/ars.2016.6749
  85. Seo, S. U., Woo, S. M., Min, K. J. and Kwon, T. K. 2018. Z-FL-COCHO, a cathepsin S inhibitor, enhances oxaliplatin- induced apoptosis through upregulation of Bim expression. Biochem. Biophys. Res. Commun. 498, 849-854. https://doi.org/10.1016/j.bbrc.2018.03.068
  86. Shi, G. P., Sukhova, G. K., Kuzuya, M., Ye, Q., Du, J., Zhang, Y., Pan, J. H., Lu, M. L., Cheng, X. W., Iguchi, A., Perrey, S., Lee, A. M., Chapman, H. A. and Libby, P. 2003. Deficiency of the cysteine protease cathepsin S impairs microvessel growth. Circ. Res. 92, 493-500. https://doi.org/10.1161/01.RES.0000060485.20318.96
  87. Singh, N., Das, P., Gupta, S., Sachdev, V., Srivasatava, S., Datta Gupta, S., Pandey, R. M., Sahni, P., Chauhan, S. S. and Saraya, A. 2014. Plasma cathepsin L: a prognostic marker for pancreatic cancer. World J. Gastroenterol. 20, 17532-17540. https://doi.org/10.3748/wjg.v20.i46.17532
  88. Sivaparvathi, M., Sawaya, R., Chintala, S. K., Go, Y., Gokaslan, Z. L. and Rao, J. S. 1996. Expression of cathepsin D during the progression of human gliomas. Neurosci. Lett. 208, 171-174. https://doi.org/10.1016/0304-3940(96)12584-2
  89. Small, D. M., Burden, R. E., Jaworski, J., Hegarty, S. M., Spence, S., Burrows, J. F., McFarlane, C., Kissenpfennig, A., McCarthy, H. O., Johnston, J. A., Walker, B. and Scott, C. J. 2013. Cathepsin S from both tumor and tumor-associated cells promote cancer growth and neovascularization. Int. J. Cancer 133, 2102-2112. https://doi.org/10.1002/ijc.28238
  90. Sukhova, G. K., Shi, G. P., Simon, D. I., Chapman, H. A. and Libby, P. 1998. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J. Clin. Invest. 102, 576-583. https://doi.org/10.1172/JCI181
  91. Sukhova, G. K., Zhang, Y., Pan, J. H., Wada, Y., Yamamoto, T., Naito, M., Kodama, T., Tsimikas, S., Witztum, J. L., Lu, M. L., Sakara, Y., Chin, M. T., Libby, P. and Shi, G. P. 2003. Deficiency of cathepsin S reduces atherosclerosis in LDL receptor- deficient mice. J. Clin. Invest. 111, 897-906. https://doi.org/10.1172/JCI200314915
  92. Tsai, J. Y., Lee, M. J., Chang, M. D., Wang, H. C., Lin, C. C. and Huang, H. 2014. Effects of novel human cathepsin S inhibitors on cell migration in human cancer cells. J. Enzyme Inhib. Med. Chem. 29, 538-546. https://doi.org/10.3109/14756366.2013.823957
  93. Tsushima, H., Ueki, A., Matsuoka, Y., Mihara, H. and Hopsu- Havu, V. K. 1991. Characterization of a cathepsin-H-like enzyme from a human melanoma cell line. Int. J. Cancer 48, 726-732. https://doi.org/10.1002/ijc.2910480516
  94. Turk, B. 2006. Targeting proteases: successes, failures and future prospects. Nat. Rev. Drug Discov. 5, 785-799. https://doi.org/10.1038/nrd2092
  95. Turk, B., Bieth, J. G., Bjork, I., Dolenc, I., Turk, D., Cimerman, N., Kos, J., Colic, A., Stoka, V. and Turk, V. 1995. Regulation of the activity of lysosomal cysteine proteinases by pHinduced inactivation and/or endogenous protein inhibitors, cystatins. Biol. Chem. Hoppe Seyler 376, 225-230. https://doi.org/10.1515/bchm3.1995.376.4.225
  96. Turk, V., Kos, J. and Turk, B. 2004. Cysteine cathepsins (proteases)--on the main stage of cancer? Cancer Cell 5, 409-410. https://doi.org/10.1016/S1535-6108(04)00117-5
  97. Turk, V., Stoka, V., Vasiljeva, O., Renko, M., Sun, T., Turk, B. and Turk, D. 2012. Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim. Biophys. Acta 1824, 68-88. https://doi.org/10.1016/j.bbapap.2011.10.002
  98. Uchiyama, Y. 2001. Autophagic cell death and its execution by lysosomal cathepsins. Arch. Histol. Cytol. 64, 233-246. https://doi.org/10.1679/aohc.64.233
  99. Vasiljeva, O., Reinheckel, T., Peters, C., Turk, D., Turk, V. and Turk, B. 2007. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr. Pharm. Des. 13, 387-403. https://doi.org/10.2174/138161207780162962
  100. Vazquez-Ortiz, G., Pina-Sanchez, P., Vazquez, K., Duenas, A., Taja, L., Mendoza, P., Garcia, J. A. and Salcedo, M. 2005. Overexpression of cathepsin F, matrix metalloproteinases 11 and 12 in cervical cancer. BMC Cancer 5, 68. https://doi.org/10.1186/1471-2407-5-68
  101. Verbovsek, U., Motaln, H., Rotter, A., Atai, N. A., Gruden, K., Van Noorden, C. J. and Lah, T. T. 2014. Expression analysis of all protease genes reveals cathepsin K to be overexpressed in glioblastoma. PLoS One 9, e111819. https://doi.org/10.1371/journal.pone.0111819
  102. Villadangos, J. A., Bryant, R. A., Deussing, J., Driessen, C., Lennon-Dumenil, A. M., Riese, R. J., Roth, W., Saftig, P., Shi, G. P., Chapman, H. A., Peters, C. and Ploegh, H. L. 1999. Proteases involved in MHC class II antigen presentation. Immunol. Rev. 172, 109-120. https://doi.org/10.1111/j.1600-065X.1999.tb01360.x
  103. Vredenburgh, J. J., Desjardins, A., Herndon, J. E., 2nd, Dowell, J. M., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Wagner, M., Bigner, D. D., Friedman, A. H. and Friedman, H. S. 2007. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res. 13, 1253-1259. https://doi.org/10.1158/1078-0432.CCR-06-2309
  104. Waghray, A., Keppler, D., Sloane, B. F., Schuger, L. and Chen, Y. Q. 2002. Analysis of a truncated form of cathepsin H in human prostate tumor cells. J. Biol. Chem. 277, 11533-11538. https://doi.org/10.1074/jbc.M109557200
  105. Wang, Z. and Zhao, X. 1998. [Expression and prognostic relation of cathepsin D in non-small cell lung cancer tissues and lymph nodes]. Zhonghua Jie He He Hu Xi Za Zhi 21, 164-166.
  106. Ward, C., Kuehn, D., Burden, R. E., Gormley, J. A., Jaquin, T. J., Gazdoiu, M., Small, D., Bicknell, R., Johnston, J. A., Scott, C. J. and Olwill, S. A. 2010. Antibody targeting of cathepsin S inhibits angiogenesis and synergistically enhances anti-VEGF. PLoS One 5, pii: e12543.
  107. Xu, J., Li, D., Ke, Z., Liu, R., Maubach, G. and Zhuo, L. 2009. Cathepsin S is aberrantly overexpressed in human hepatocellular carcinoma. Mol. Med. Rep. 2, 713-718.
  108. Yang, M., Liu, J., Shao, J., Qin, Y., Ji, Q., Zhang, X. and Du, J. 2014. Cathepsin S-mediated autophagic flux in tumor-associated macrophages accelerate tumor development by promoting M2 polarization. Mol. Cancer 13, 43. https://doi.org/10.1186/1476-4598-13-43
  109. Yang, Y., Lim, S. K., Choong, L. Y., Lee, H., Chen, Y., Chong, P. K., Ashktorab, H., Wang, T. T., Salto-Tellez, M., Yeoh, K. G. and Lim, Y. P. 2010. Cathepsin S mediates gastric cancer cell migration and invasion via a putative network of metastasis-associated proteins. J. Proteome Res. 9, 4767-4778. https://doi.org/10.1021/pr100492x
  110. Zhang, L., Wang, H., Xu, J., Zhu, J. and Ding, K. 2014. Inhibition of cathepsin S induces autophagy and apoptosis in human glioblastoma cell lines through ROS-mediated PI3K/AKT/mTOR/p70S6K and JNK signaling pathways. Toxicol. Lett. 228, 248-259. https://doi.org/10.1016/j.toxlet.2014.05.015
  111. Zhao, Y. and Adjei, A. A. 2015. Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor. Oncologist 20, 660-673. https://doi.org/10.1634/theoncologist.2014-0465
  112. Zhu, D. M. and Uckun, F. M. 2000. Cathepsin inhibition induces apoptotic death in human leukemia and lymphoma cells. Leuk. Lymphoma 39, 343-354. https://doi.org/10.3109/10428190009065834
  113. Zhu, D. M. and Uckun, F. M. 2000. Z-Phe-Gly-NHO-Bz, an inhibitor of cysteine cathepsins, induces apoptosis in human cancer cells. Clin. Cancer Res. 6, 2064-2069.